Pediatrix Medical Group, Inc.

DB:PDC Stock Report

Market Cap: €710.1m

Pediatrix Medical Group Valuation

Is PDC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Unter dem Marktwert

  • Deutlich unter dem Marktwert

  • Price-To-Sales gegen Gleichaltrige

  • Price-To-Sales gegen Industrie

  • PM vs. Fair Ratio

  • Analysten-Prognose

Share Price vs Fair Value

What is the Fair Price of PDC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Unter dem Marktwert: PDC (€7.7) wird unter unserer Schätzung des Fair Value (€21.02) gehandelt.

Deutlich unter dem Marktwert: PDC wird um mehr als 20 % unter dem Marktwert gehandelt.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PDC?

Other financial metrics that can be useful for relative valuation.

PDC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.6x
Enterprise Value/EBITDA6.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PDC's PS Ratio compare to its peers?

The above table shows the PS ratio for PDC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
SYAB SYNLAB
0.9x7.5%€2.3b
FME Fresenius Medical Care
0.5x3.7%€10.3b
FRE Fresenius SE KGaA
0.6x4.3%€14.2b
V3V VITA 34
1.1x3.1%€82.6m
PDC Pediatrix Medical Group
0.4x3.3%€769.6m

Price-To-Sales gegen Gleichaltrige: PDC ist ein guter Wert, wenn man sein Price-To-Sales Verhältnis (0.4x) mit dem Durchschnitt der anderen Unternehmen (0.8x) vergleicht.


Price to Earnings Ratio vs Industry

How does PDC's PE Ratio compare vs other companies in the DE Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.4%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.4%
n/an/an/a
No more companies

Price-To-Sales gegen Industrie: PDC ist aufgrund seines Price-To-Sales Verhältnisses (0.4x) im Vergleich zum European Healthcare Branchendurchschnitt (0.7x) ein guter Wert.


Price to Sales Ratio vs Fair Ratio

What is PDC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PDC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.6x

PM vs. Fair Ratio: PDC ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Sales (0.4x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Sales (0.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PDC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.45
€8.42
-0.3%
6.2%€9.29€7.43n/a7
Mar ’25€8.30
€8.65
+4.2%
9.3%€10.17€7.39n/a7
Feb ’25€8.55
€9.01
+5.3%
7.0%€10.05€8.22n/a7
Jan ’25€8.45
€9.23
+9.2%
10.1%€10.99€8.24n/a7
Dec ’24€7.55
€9.78
+29.5%
10.3%€11.03€8.27n/a7
Nov ’24€10.40
€13.70
+31.7%
3.4%€14.17€13.23n/a6
Oct ’24€11.80
€14.04
+19.0%
5.4%€14.97€13.10n/a6
Sep ’24€12.90
€14.75
+14.4%
18.0%€21.02€12.79n/a7
Aug ’24€12.30
€14.59
+18.6%
18.3%€20.98€12.77n/a7
Jul ’24€13.00
€14.59
+12.3%
18.3%€20.98€12.77n/a7
Jun ’24€12.40
€14.59
+17.7%
18.3%€20.98€12.77n/a7
May ’24€12.80
€15.49
+21.0%
16.0%€20.87€12.71n/a7
Apr ’24€13.30
€16.68
+25.4%
13.5%€21.69€14.15€9.258
Mar ’24€14.60
€16.68
+14.3%
13.5%€21.69€14.15€8.308
Feb ’24€14.00
€16.57
+18.3%
20.4%€24.85€12.88€8.558
Jan ’24€13.90
€17.21
+23.8%
20.0%€25.63€13.29€8.458
Dec ’23€15.20
€17.55
+15.5%
21.5%€26.92€13.46€7.558
Nov ’23€19.60
€21.51
+9.8%
15.6%€28.86€16.49€10.408
Oct ’23€17.10
€20.87
+22.1%
15.0%€27.50€15.72€11.808
Sep ’23€17.30
€20.87
+20.7%
15.0%€27.50€15.72€12.908
Aug ’23€22.00
€21.94
-0.3%
16.8%€29.47€15.72€12.309
Jul ’23€20.40
€20.68
+1.4%
16.9%€28.49€15.19€13.009
Jun ’23€17.70
€20.83
+17.7%
18.0%€27.98€14.92€12.409
May ’23€18.70
€23.60
+26.2%
10.5%€29.39€20.86€12.809
Apr ’23€21.00
€25.53
+21.6%
8.4%€28.38€21.97€13.309

Analysten-Prognose: Das Kursziel ist niedriger als der aktuelle Aktienkurs.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.